In this episode of CXO Talks, PharmaShots speaks with Vikas Sharma, Chief Business Officer at QurAlis, a biotech company leading the development of precision medicines for neurodegenerative diseases
Vikas discusses the company’s FlexASO platform, a next-generation RNA-targeting technology that tackles the root causes of neurological diseases
Vikas also highlights QurAlis’ lead candidates, QRL-201 and QRL-101,…
Shots:
Harnessing in-depth research and data-driven insights, PharmaShots unveils its definitive report on the Top 20 Countries in Healthcare Innovation 2025, a comprehensive guide to the nations setting global benchmarks in healthcare advancement
Through a meticulous blend of quantitative and qualitative analysis, PharmaShots delved into the multifaceted dimensions of healthcare innovation, spotlighting emerging trends such…
Shots:
As life sciences organizations increasingly adopt integrated data, AI, and advanced analytics, CRM platforms are becoming powerful tools to anticipate customer needs, personalize engagements, and measure impact in real-time across multiple channels
In the coming years, CRM will transform into a strategic intelligence hub, empowering teams to make data-driven decisions and helping companies…
Shots:
Given the high variability and subjectivity of traditional clinical scales, there is an urgent need for objective biomarkers to assess CNS disease progression more reliably
NeuraLight is at the forefront of precision neurology, developing objective and sensitive biomarkers that bring greater accuracy and consistency to CNS research
In this exclusive conversation, Edmund…
Shots:
In this captivating episode of the CXO Talks Podcast, PharmaShots sits down with Josh Wittner, President, North America at Gene By Gene, to explore the company’s evolution and impact in the field of genetic testing
Gene By Gene, a leading commercial genetic testing company, delivers cutting-edge genetic data services spanning a broad range of…
Shots:
Citius Pharmaceuticals celebrates its first-ever FDA approval with Lymphir, a novel therapy for relapsed or refractory cutaneous T-cell lymphoma
In an exclusive conversation, Leonard Mazur, Co-Founder and CEO at Citius Pharmaceuticals, shares insights on Lymphir’s launch strategy and its potential impact on the oncology landscape
Leonard also highlights Mino-Lok, Citius’ innovative…
Day 1 Breakdown
The #PCG2025 Symposium commenced on an inspiring note, setting the stage for two days of insightful discussions, collaborations, and knowledge exchange.
Opening Session
Dr. Ratnesh Jain, Founder & Director, Mumbai Cluster, delivered the inaugural address, sharing his vision of bringing together pharma professionals, R&D experts, CXOs, and academicians to accelerate advancements in…
Shots:
Enable Injections recently shared survey findings indicating that many oncology assets with strong commercial potential are often prematurely abandoned or deprioritized due to challenges in formulating small volumes (<3 mL) for subcutaneous delivery.
To address this need, Enable Injections developed enFuse, an innovative, hands-free, wearable drug delivery platform with a discreet, hidden needle that…
Shots:
Welcome to the September edition of Know Your Investor, featuring leading investors fuelling healthcare & life sciences
This edition spotlights Cormorant Asset Management, an investment firm focused on biotechnology and healthcare companies
In 2024, Cormorant completed 31 investments ~$3.88B, spanning PIPEs, private financings, IPO, and venture rounds. For the full report, contact us at…
EVERYONE has a heroic story to tell, their own legend to fulfill and HLTH is forging ahead into new realms of possibilities, gathering 12,000+ influential leaders, executives and visionaries who are passionately creating the next generation of healthcare. At HLTH you can foster meaningful connections, gain insights on cutting-edge trends, enhance your professional journey, or…

